Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
Condition(s) studied
Investigational drug(s) / intervention(s)
Rimonabant: Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.
Placebo: Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.
Study summary
The mail goal of this clinical trial is assess the effect of rimonabant in walking ability in people who experienced a stroke at least 12 months before enrollment.
It will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.
The study will also help to learn about the safety of rimonabant.
Eligibility
Primary outcome measure(s)
- Six-Minute Walk Test (6MWT) — Baseline to end of follow-up (day 135)
The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospital Universitario de Albacete | Albacete | Albacete | |
| Institut Guttmann | Badalona | Barcelona | |
| Jiménez Lucena S.L. (CLÍNICA I+TÚ) | Córdoba | Córdoba | |
| Hospital Los Madroños | Brunete | Madrid | |
| Hospital Clínico San Carlos (HCSC) | Madrid | Madrid | |
| Hospital Universitario La Paz | Madrid | Madrid |
More Sinfatin S.L trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07913763 on ClinicalTrials.gov ↗ ← All trials in Spain